WT1 and glioblastoma: Commensurate with this perspective, two groups in Japan have developed an anti-WT1 peptide vaccine aimed at reducing WT1 protein activity in glioblastoma multiforme patients that is currently undergoing phase II clinical trial (Izumoto et al., 2008; Oji et al., 2016).